Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women
NCT ID: NCT02651259
Last Updated: 2021-11-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
50 participants
INTERVENTIONAL
2017-03-13
2019-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study enrolled HIV-1-infected and HIV-1-uninfected pregnant women with latent TB and their infants into two cohorts based on gestation. Cohort 1 participants were enrolled in their second trimester (greater than or equal to 14 to less than 28 weeks), and Cohort 2 participants were enrolled in their third trimester (greater than or equal to 28 to less than or equal to 34 weeks). All participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits. Study researchers would perform an interim analysis to assess the PK of RPT during the study, and a dose adjustment could have been recommended based on this analysis.
Study visits occurred at days 0-3, once a week through week 11, and once a month until 24 weeks after delivery. Visits would include physical examinations, obstetrical exams, and blood collection. Infants were followed monthly until 24 weeks after birth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1 (pregnant women enrolled in the second trimester)
Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
Rifapentine (RPT)
900 mg of RPT
Isoniazid (INH)
900 mg of INH
Pyridoxine (vitamin B6)
25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
Cohort 2 (pregnant women enrolled in the third trimester)
Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
Rifapentine (RPT)
900 mg of RPT
Isoniazid (INH)
900 mg of INH
Pyridoxine (vitamin B6)
25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rifapentine (RPT)
900 mg of RPT
Isoniazid (INH)
900 mg of INH
Pyridoxine (vitamin B6)
25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At screening, evidence by ultrasound of a viable singleton pregnancy with an estimated gestational age at enrollment of greater than or equal to 14 weeks through less than or equal to 34 weeks as per screening ultrasound (see protocol for more information)
* Had at least one of the following risk factors for TB:
* Per participant report, the participant was a household contact (see NOTE below) of a known active pulmonary TB patient
* Per medical records, confirmation of HIV-1 infection (see protocol for more information) and a single positive tuberculin skin test (TST) or interferon gamma release assay (IGRA) at any time in the past. If not available in medical record, perform at screening.
NOTE: A household contact was defined as a person who currently lives or lived in the same dwelling unit and shares or shared the same housekeeping arrangements and who reported exposure within the past two years to an adult index case with pulmonary TB. Shared housekeeping arrangements were defined as sleeping under the same roof as the index TB case for at least seven consecutive days during the one month prior to the index case TB diagnosis.
* Documentation of HIV-1 infection status, or confirmation of HIV-1 infection status (if unknown or undocumented). Confirmation of HIV-1 infection was defined as positive results from two samples (described in the protocol) collected at different time points. All samples tested must be whole blood, serum, or plasma. As this study was being conducted under an IND, all test methods should be FDA-approved, if available. If FDA-approved methods were not available, test methods should be verified according to Good Clinical Laboratory Practice (GCLP) and approved by the IMPAACT Laboratory Center. More information on this criterion was available in the protocol.
* If HIV-1-infected, documented current prescription of efavirenz (EFV) + 2 nucleoside reverse transcriptase inhibitor (NRTI) regimen and reported taking regimen for at least two weeks prior to enrollment (regimens containing protease, integrase, or entry inhibitors were not permitted)
* Documented laboratory values obtained within 14 days prior to enrollment:
* Hemoglobin greater than or equal to 7.5 g/dL
* White blood cell count greater than or equal to 1500 cells/mm\^3
* Alanine transaminase (ALT) less than 2.5 times the upper limit of normal (ULN)
* Total bilirubin less than 1.6 times the ULN
* Absolute neutrophil count (ANC) greater than or equal to 750 cells/mm\^3
* Platelet count greater than or equal to 100,000/mm\^3
* Per participant report at screening, intent to remain in the current geographical area of residence for the duration of the study
* Per participant report at screening, able to swallow whole tablets
* Per participant report, intention to keep the pregnancy
* Per participant report, willingness to permit infant to participate in the study
Exclusion Criteria
* Participant report of personal history of INH- or rifampin-resistant, multi-drug resistant (MDR), or extensively drug-resistant (XDR) TB
* Participant report of personal history of active TB in the past 2 years
* Participant report of previous treatment for latent tuberculosis infection (LTBI)
* Household contact (as defined above) with known active MDR or XDR TB disease
* Known major fetal abnormality as detected on ultrasound
* Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation
* Known history of liver cirrhosis at any time prior to study entry
* Per participant report and/or medical records, evidence of acute clinical hepatitis, such as a combination of abdominal pain, jaundice, dark urine, and/or light stools within 90 days prior to entry
* Participant report and/or medical records of peripheral neuropathy Grade 2 or higher within 90 days prior to entry
* Current use or history of active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
* Participant report and/or clinical evidence of porphyria
* Any other condition that, in the opinion of the investigator of record (IoR)/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives, including taking the study medication
* Planned or current participation in an interventional drug study
* Current use of any prohibited or precautionary medications (see protocol for more information), including didanosine (DDI) or stavudine (D4T)
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jyoti S. Mathad, MD, MSc
Role: STUDY_CHAIR
Weill Medical College of Cornell University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
Port-au-Prince, , Haiti
Kenya Medical Research Institute / Walter Reed Project Clinical Research Center, Kericho CRS
Kericho, , Kenya
Malawi CRS
Lilongwe, Central Malawi, Malawi
Siriraj Hospital ,Mahidol University NICHD CRS
Bangkok, Bangkoknoi, Thailand
Harare Family Care CRS
Harare, , Zimbabwe
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mathad JS, Savic R, Britto P, Jayachandran P, Wiesner L, Montepiedra G, Norman J, Zhang N, Townley E, Chakhtoura N, Bradford S, Patil S, Popson S, Chipato T, Rouzier V, Langat D, Chalermchockcharoentkit A, Kamthunzi P, Gupta A, Dooley KE. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. Clin Infect Dis. 2022 May 3;74(9):1604-1613. doi: 10.1093/cid/ciab665.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan: Final Safety Statistical Analysis Plan
Document Type: Statistical Analysis Plan: Final PK Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Severity and laboratory tests will be graded per the DAIDS Table for Grading Adult and Pediatric Adverse Events, Version 2.0(dated November 2014 available on the RSC website)
Requirements, definitions and methods for expedited reporting of adverse events (AEs) are outlined in Version 2.0 of the DAIDS EAE Manual
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12026
Identifier Type: REGISTRY
Identifier Source: secondary_id
IMPAACT 2001
Identifier Type: -
Identifier Source: org_study_id